Psyence Biomedical Ltd

World's First Nasdaq listed Nature-Derived Psilocybin Biopharma arrives on Wall Street. Thank you Nasdaq for welcoming Psyence Biomedical Ltd (NASDAQ:PBM) #FollowThePsyence

If a psychedelic biopharma investment can be described as a health care investment, as it was by Benzinga when it reported an update on Psyence Biomedical Ltd then maybe one day mental health issues will be described as health issues. #Progress https://lnkd.in/egFBzM3a

Throw-back Thursday, to when we ask: Why ibogaine? Journalist Rowan Dunne shares an update: “By combining our manufacturing expertise with Psyence Biomedical Ltd 's clinical development capabilities, we are creating a powerful platform to explore the full potential of ibogaine and psilocybin in addressing addiction and mental health disorders,” PsyLabs chief executive, Tony Budden, said.

A warm welcome to Washington, D.C., to Southern Star Research and Robert Kent. Our Psyence Biomedical Ltd collaboration with Southern Star Research is a pivotal step forward in our clinical development plan as we accelerate our ongoing Phase llb non-synthetic nature-derived psilocybin clinical trial with a focus on Adjustment Disorder in patients diagnosed with cancer. Dr. David Lloyd founder of Southern Star Research has welcomed Psyence Biomedical Ltd to this collaboration saying: "this partnership represents a significant step in our long-term commitment to advancing novel psychedelic-assisted therapies." We think so too. Welcome Southern Star Research and great to have Robert Kent in our nation's capital this week for the The World Vaccine Congress. Your team does it all!

Physician-led and patient-centered, Psyence Biomedical Ltd shuns hype and is guided by evidence-based science and the wisdom of its Scientific Advisory Board, whose chair Albert Garcia-Romeu, PhD is a founding member and Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research Join Dr. Garcia-Romeu when he leads a June workshop with the American Psychological Association that includes an overview of "the science of psychedelics, beginning with a discussion of their pharmacology and historical use. Early and contemporary research studies investigating drugs like LSD, psilocybin, and MDMA will be presented, describing how these substances work, their risks, and their therapeutic potentials." Sign up below. See you there!

From Ibogaine to Ethics, Psyence Biomedical Ltd welcomes this Global Wellness Institute trends update reported by our Washington, D.C.-based Chief of Global Impact, Mary-Elizabeth Gifford.

Why ibogaine? Journalist Rowan Dunne shares an update: “By combining our manufacturing expertise with Psyence Biomedical Ltd's clinical development capabilities, we are creating a powerful platform to explore the full potential of ibogaine and psilocybin in addressing addiction and mental health disorders,” PsyLabs chief executive, Tony Budden, said. Alongside companies like Compass Pathways (NASDAQ: CMPS), atai Life Sciences (NASDAQ: ATAI) (ETR: 9VC), MindMed (Mind Medicine) Inc (NASDAQ: MNMD) and GH Research plc (NASDAQ: GHRS) (FRA: 1KA), Psyence is one of the few psychedelic drug developers listed on the Nasdaq Exchange." And the only biopharma working to develop safe, responsible, FDA-approved candidates with a focus on nature-derived psilocybin and ibogaine. . . https://lnkd.in/edv6KB3X

What happens when nature-derived Ibogaine meets Wall Street? Adam Jackson in this issue of the Crain Communications publication Green Market Report shares how Psyence Biomedical Ltd, recognized for its achievement as first biopharma with a non-synthetic psilocybin pharmaceutical candidate to list on Nasdaq, now includes Ibogaine in its nature-derived psychedelic portfolio. https://lnkd.in/erXGs6yz

Another first from Psyence Biomedical Ltd https://lnkd.in/eMmYhVG2

Nature-derived Ibogaine meets Wall Street. In another first achieved by Psyence Biomedical Ltd, the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to list on the Nasdaq, now includes Ibogaine in its focus. Today it was announced that  Psyence Biomedical Ltd secured a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence Biomedical Ltd's integrated development strategy, explains CEO Dr. Neil Maresky ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas.  Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Psyence Biomedical Ltd is one of the world's few vertically integrated biopharmas with a focus on developing FDA-approved psychedelic-based pharmaceutical therapeutics.